After a five-year hiatus, Betta Pharmaceuticals Co., Ltd. is once again knocking on the doors of the Hong Kong stock exchange, carrying the mantle of being the "first domestic innovative targeted therapy stock" on the A-share market. China International Capital Corporation serves as the sole sponsor for this listing attempt.

Behind the glow of its 2011 success with Icotinib and years of consistent profitability, this veteran A-share pharmaceutical firm has unveiled a series of unsettling facts for investors: the compound patent for its top-selling drug expired three years ago with generics already approved; research and development spending as a share of revenue has plummeted from 40% to just over 10%; and a dispute with a partner over a RMB 180 million milestone payment remains unresolved.

Walking Through the Growth Ledger

Founded in 2003, Betta Pharmaceuticals has successfully transitioned from a biotech focused on drug discovery and development to a fully integrated biopharmaceutical company operating across the entire value chain, complete with commercial capabilities. To date, it has commercialized nine drugs, with Icotinib (Conmana®/Kaimena®, an EGFR TKI), Ensartinib (Ensacove®/Beimena®, an ALK TKI), and Vorolanib (Fumeina®, a VEGFR/PDGFR inhibitor) each being the first domestically approved drug in their respective classes or the first to target specific indications for the global market in China.

Between 2023 and 2025, Betta Pharmaceuticals' total revenue grew from RMB 2.456 billion to RMB 3.609 billion, with year-on-year growth rates of 17.7% and 24.8%, respectively. In the first half of 2026, revenue further increased by 14.1% to RMB 1.976 billion. However, a closer look reveals that the combined revenue share of Icotinib and Befotertinib has been steadily declining, from 66.9% in 2023 to 41.3% in the first half of 2026. The company's growth engine has clearly shifted; Ensartinib's sales saw a compound annual growth rate of 43.3% from 2023 to 2025, while Bevacizumab injection grew at a 52.8% CAGR over the same period. These two products have replaced Icotinib as the primary growth drivers.

Yet, Betta Pharmaceuticals' profitability has not kept pace with its top-line growth. The prospectus shows a net profit of RMB 387 million in 2024 (with attributable net profit of RMB 403 million), up 16% year-on-year. However, 2025 saw a counter-trend decline of 26% to RMB 286 million (attributable net profit of RMB 305 million), with the net profit margin narrowing from 13.4% to 7.9%. The company attributes this to factors including increased commercialization spending boosting sales expenses, an unrealized loss of RMB 58.68 million from a subsidiary's investment in trading financial assets, and amortization of intangible assets beginning after the completion of a new plant and the US approval of Ensartinib.

In the first half of 2026, profit surged 123.9% year-on-year to RMB 293 million (attributable net profit of RMB 302 million). However, nearly half of this growth was propped up by a realized gain of RMB 72.7 million from financial assets. Excluding this investment income, the quality of profits warrants a more skeptical review.

The most solid aspect of the company's fundamentals is its cash flow. From 2023 to 2025, net cash generated from operating activities remained stable between RMB 911 million and RMB 914 million annually. The net profit cash conversion rate consistently exceeded 200%, reaching 318% in 2025. This indicates that the book profits are backed by real cash recovery, lending substance to the "quality" of earnings.

The Lingering Shadow of an Aging Blockbuster

Icotinib is both the starting point and the lifeblood of Betta Pharmaceuticals. According to the prospectus, as China's first self-developed small-molecule targeted anti-cancer drug, Icotinib has generated cumulative sales exceeding RMB 18 billion since its 2011 launch and has surpassed RMB 1 billion in annual sales for nine consecutive years since 2016. It stands as a rare "evergreen" among domestic EGFR TKIs.

Even under the successive assaults of third-generation EGFR TKIs like Osimertinib, Almonertinib, and Furmonertinib, it remains the only first-generation product able to directly compete with its third-generation counterparts. This was once the company's proudest demonstration of its "lifecycle management" capability. However, the prospectus declares a turning point in this moat defense with a simple statement: the compound patent for Icotinib expired in 2023, although related patents (e.g., crystal forms) offer protection extending to 2029–2034. In July 2026, the first generic version received marketing approval in China.

Generic entry almost inevitably leads to low-price market penetration. Once competition intensifies, Icotinib could be drawn into national or regional centralized volume-based procurement, facing further price reduction pressure. The company is not without countermeasures, as it advances real-world studies for Icotinib in the post-operative treatment of high-risk early-stage lung cancer, attempting to expand its approved indications further.

R&D Cooling Off: From 40.8% to 11.7%

If patent expiry is an external inevitability, the contraction in R&D spending is a choice made by Betta Pharmaceuticals itself. The prospectus details a decline in total R&D investment (including both expensed and capitalized development costs) from RMB 1.002 billion in 2023 to RMB 717 million in 2024 and RMB 574 million in 2025, further dropping to RMB 231 million in the first half of 2026.

Correspondingly, R&D investment as a percentage of revenue has fallen sharply, from 40.8% in 2023 to 24.8% in 2024, 15.9% in 2025, and just 11.7% in the first half of 2026. When placed within the industry context, this disparity becomes even more glaring. According to public annual reports, Hengrui Medicine's cumulative R&D investment in 2025 was RMB 8.724 billion, representing 27.58% of its revenue; BeiGene's 2025 R&D spending was RMB 15.508 billion, about 40.6% of revenue; even Innovent Biologics, whose R&D expense ratio fell to 20.1%, still significantly exceeds Betta Pharmaceuticals' level. (Note: Hengrui's figure includes capitalized R&D, while BeiGene and Innovent use expensed R&D, and Betta's figure includes capitalized R&D.)

For a company that positions itself as an "innovative drug" developer and uses this as its core selling point for the IPO, having its R&D intensity fall below the industry mainstream and decline year after year is the most difficult discrepancy to reconcile in the entire prospectus. The high growth of Ensartinib and Bevacizumab injection largely stems from the scaling up of existing products and the consolidation of licensed-in products (such as Pertuzumab, Trastuzumab, and Recombinant Human Albumin). The breakthrough from its self-developed pipeline is still pending. Its self-developed CDK4/6 inhibitor, Tirisethyl, was only approved in July 2025 and remains small in scale. Among its 15 pipeline candidates in development, most are still in early-stage (Phase I/II) trials. The size of its R&D team also pales in comparison to leading innovative drug companies; as of June 30, 2026, Betta Pharmaceuticals' R&D team comprised 288 people, including 29 with doctoral degrees.

The RMB 180 Million Milestone Payment Dispute

Beyond the patent expiry, Betta Pharmaceuticals proactively disclosed a cooperation dispute with InventisBio concerning milestone payments related to Befotertinib (Saimena®). The story began in December 2018 when Betta Pharmaceuticals entered into a cooperation agreement with InventisBio, obtaining exclusive rights to develop, manufacture, and commercialize Befotertinib in mainland China, Hong Kong, and Taiwan, along with jointly owning the related intellectual property.

Under the agreement, InventisBio is entitled to an upfront payment and a series of regulatory and sales milestone fees. The total agreement amount (including sales milestones and royalty fees) is capped at RMB 400 million to RMB 600 million, with RMB 180 million representing the regulatory milestones already triggered. The prospectus acknowledges that certain regulatory milestone payments totaling RMB 180 million under the agreement have been triggered and constitute a payable for the company.

However, the company, "after considering commercial factors and the long-term nature of the cooperation," is currently in negotiations with InventisBio regarding the payment of these fees. As of the disclosure date, only RMB 80 million of this amount had been paid in December 2025, leaving approximately RMB 100 million outstanding. The company's language emphasizes that the "overall cooperation relationship remains friendly and constructive" and intends to resolve the matter through amicable negotiation. However, the prospectus also concedes that "there is no guarantee that the consultations will always result in terms acceptable to both parties, nor that they will not escalate to the point where other resolution mechanisms are required." In essence, a commercial disagreement over RMB 100 million currently exists in the gray area between "negotiated settlement" and "legal proceedings."

In summary, Betta Pharmaceuticals is one of the few innovative drug companies to have achieved sustained profitability, with virtually no loss-making record since its commercial debut in 2011. Ensartinib received FDA approval in the U.S. in December 2024, marking the first domestically developed ALK TKI to go global and the first time a Chinese-discovered lung cancer targeted therapy has entered the American market. These achievements are rare positive examples within the "domestic innovative drug" narrative.

Yet, the prospectus also exposes the structural contradictions within the company. It enjoys the brand premium of being an "innovative drug" developer, yet appears to be sliding towards a growth model driven by sales and licensing-in. It has nine marketed products but is highly dependent on two lung cancer targeted therapy categories, with its largest product teetering on the edge of a patent cliff. It proclaims itself an "innovation engine," yet its R&D intensity is not only declining year by year but also falls far below that of its peers. And the unresolved RMB 180 million dispute adds another layer of uncertainty to this listing journey.